Komatsu Hisateru, Morimoto Junya, Yamashita Yoshito, Ikeya Tetsuro, Yamazoe Sadaaki, Kodai Shintaro, Shimizu Sadatoshi, Yamamoto Atsushi, Kanazawa Akishige, Inoue Toru, Tsukamoto Tadashi, Ikehara Teruyuki, Nishiguchi Yukio
Dept. of Gastroenterological Surgery, Osaka City General Hospital.
Gan To Kagaku Ryoho. 2011 Nov;38(12):2339-41.
CASE 1: A 67-year-old man had advanced gastric cancer with lymph node metastasis (cT3N1M0, cStage IIIA). S-1 120 mg was administered for 21 days as neoadjuvant chemotherapy (NAC). A month later, total gastrectomy (with splenectomy) was performed. Histopathological examination revealed no cancer cells in the gastric wall and dissected lymph nodes. CASE 2: A 62-year-old man had advanced gastric cancer with lymph node metastasis (cT4aN2M0, cStage IIIB). He was treated with daily oral administration of S-1 120 mg (28-day administration followed by 7-day rest, and then 14- day administration) as NAC. A month later, total gastrectomy was performed. Histopathological examination revealed no cancer cells in the gastric wall and dissected lymph nodes. In both cases, the pathological effect was judged as grade 3. This suggests that NAC with S-1 mono-therapy can have a distinct therapeutic value for advanced gastric cancer.
病例1：一名67岁男性患有伴有淋巴结转移的进展期胃癌（cT3N1M0，c期IIIA）。给予S-1 120毫克，进行21天的新辅助化疗（NAC）。一个月后，实施全胃切除术（连同脾切除术）。组织病理学检查显示胃壁和切除的淋巴结中无癌细胞。病例2：一名62岁男性患有伴有淋巴结转移的进展期胃癌（cT4aN2M0，c期IIIB）。他接受每日口服S-1 120毫克的治疗（给药28天，随后休息7天，然后给药14天）作为新辅助化疗。一个月后，实施全胃切除术。组织病理学检查显示胃壁和切除的淋巴结中无癌细胞。在这两个病例中，病理效果均判定为3级。这表明S-1单药新辅助化疗对进展期胃癌可能具有显著的治疗价值。
Zotero 插件